Cartagenia Partners with MedGenome to Provide Pathology Laboratories Access to Extensive Cancer Variant Knowledge Base
BOSTON and SAN FRANCISCO, Jan. 22, 2015 /PRNewswire/ — Cartagenia, the leader in providing genetic labs and clinicians with software-based workflow support for variant assessment, lab reporting, and access of relevant knowledge bases, today announced a partnership with MedGenome Inc, the developer of the OncoMD Cancer knowledge base.
OncoMD is an industry-leading cancer analytics platform that includes a curated, proprietary knowledge base of 1.7 million cancer mutations, with relevant functional information, sensitivity to drugs and potential clinical trials for enrollment. Curated and accurate annotations of cancer-related mutations can help pathologists and oncologists personalize cancer treatment and review available therapy options.
Cartagenia’s customers that have adopted the Bench Lab NGS platform for their somatic genetic sequencing analysis and reporting workflow will now be able to get access to the OncoMD knowledge base which they can integrate with their own proprietary information to help them analyze their patients’ genetic data and draft physician- ready reports.
“The combination of our OncoMD cancer knowledge base and Cartagenia’s unique software platform offer clinical and pathology laboratories two important tools to allow them to analyze and interpret their own patient data,” said Amit Chaudhuri, VP Research & Development.
“We are very excited to work closely with Cartagenia to bring a robust medical informatics solution to the global clinical laboratory market,” said Sam Santhosh, CEO of MedGenome.
Herman Verrelst, Cartagenia’s CEO, commented: “The ability to personalize medicine and understand a patient’s unique cancer is at the forefront of modern oncology and, to this end, it is important for our customers to have tools like OndoMD to help them analyze and assess the genetic profile of their patients. We look forward to working closely with MedGenome to better serve our customers and help them better understand their patients’ needs.”
The MedGenome partnership is one of a number of business relationships set up by Cartagenia that will help its customers keep up with the scale and pace of change in medical and scientific knowledge associated with Next-Generation Sequencing (NGS) cancer panels. In November, Cartagenia announced a partnership with CollabRx that provides Cartagenia customers access to CollabRx’s industry-leading treatment information resources and services.
Cartagenia has built the tools for labs to integrate their internal knowledge into their clinical variant assessment and reporting pipelines in a robust, traceable, and versioned fashion. In addition, Cartagenia created the necessary infrastructure to do the same with established public resources used by the clinical scientific community, and content resources from a range of premium partners. In this way, labs are at liberty to choose, validate and integrate their preferred content into their routine pipelines.
About MedGenome
MedGenome is a leading genomics company dedicated to helping doctors and researchers around the world develop and tailor treatments specifically for each patient’s unique genetic code. Through its work with thousands of doctors, hospitals and patients across India, MedGenome leverages the power of big data, next-generation DNA sequencing techniques and sophisticated clinical and analytics capabilities to drive research, disease risk assessment, management, treatment and patient outcomes. Its proprietary OncoMD Cancer Analytics Platform offers insight into more than 1.7 million cancer-related mutations via an interactive web-based portal to help physicians and hospitals pinpoint patients’ mutation hotspots, identify prevalent cancer types, flag potential variant to therapies, and link mutations to open clinical trials. The company is backed by a team of industry veterans with deep experience in genomics and big data technologies. For more information, visit www.medgenome.com.
About Cartagenia
Cartagenia supplies diagnostic support software, database systems, and related services to genetic labs, pathology labs and clinicians, enabling them to perform clinically relevant genetic analyses quickly and efficiently, and offer patients and carers high-quality genetic interpretation and counselling.
Cartagenia Bench Lab allows automation of variant assessment protocols and lab report generation for structural and molecular variant assays such as Arrays, Sanger and Next Generation Sequencing. It supports communication with referring physicians, allows labs and clinicians to put variants in their clinical context, and supports confident data sharing.
The Cartagenia Bench platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab addresses the specific needs of genetic diagnostic labs and clinicians.
Cartagenia Bench is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304.
